Myocardial Revascularization Strategies in ST Elevation Myocardial Infarction Without Urgent Revascularization:...

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• ST-segment elevation myocardial infarction (STEMI) is a critical condition requiring timely intervention.
• The optimal revascularization strategy for STEMI patients not undergoing immediate (<48 hours) intervention remains a subject of investigation.
• Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery are primary revascularization methods.

Purpose of the Study:

• To compare the clinical outcomes of STEMI patients treated with PCI versus CABG when revascularization occurs between 48 hours and 90 days post-initial hospitalization.
• To evaluate the association of surgical versus percutaneous revascularization with mortality, rehospitalization, and major adverse events.

Main Methods:

• Analysis of a French administrative hospital discharge database (2010-2019) for STEMI patients undergoing first PCI or CABG between 48 hours and 90 days.
• Utilized propensity score matching to create comparable groups for outcome analysis.
• Compared rates of all-cause death, cardiovascular death, heart failure rehospitalization, stroke, and major bleeding.

Main Results:

• In a matched cohort of 12,012 patients, surgical revascularization was linked to significantly lower rates of all-cause death (5.1% vs. 7.1%) and cardiovascular death (2.6% vs. 3.1%).
• Rehospitalization for heart failure was less frequent following CABG (5.5% vs. 7.5%).
• Major bleeding events were more common after PCI (4.6% vs. 6.1%), while stroke incidence did not differ significantly.

Conclusions:

• For STEMI patients who do not receive urgent revascularization, surgical revascularization is associated with superior outcomes compared to PCI.
• Individual consideration of CABG as an alternative to PCI is warranted in this patient population.
• Delayed revascularization in STEMI may benefit from a surgical approach for improved survival and reduced heart failure readmissions.